← FDA DRUG APPROVALS

FDA ANDA · ANDA077129

RIVASTIGMINE TARTRATE

Sponsor: WATSON LABS

APPLICATION
ANDA077129
TYPE
ANDA
ORIGINAL APPROVAL
2008-01-08
LATEST ACTION
2021-09-15
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 4.5MG BASE · CAPSULE · ORAL
RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 1.5MG BASE · CAPSULE · ORAL
RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 6MG BASE · CAPSULE · ORAL
RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 3MG BASE · CAPSULE · ORAL

Approval history

2021-09-15Labeling · Supplement 4 · standardAP
2021-09-15Labeling · Supplement 5 · standardAP
2015-11-20Labeling · Supplement 2 · standardAP
2015-11-20Labeling · Supplement 3 · standardAP
2008-01-08OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →